Patrick Campbell

Jonathan Barratt, PhD, discusses his excitement surrounding data and programming at the American Society of Nephrology's Kidney Week 2024, with a focus on IgAN.

Antonio Anzueto, MD, discusses how dupilumab fits into treatment algorithms for patients with uncontrolled COPD.

Stephanie Christenson, MD, discusses the impact of recent regulatory approvals and pipeline movement for chronic obstructive pulmonary disease.

Linda Gillam, MD, MPH, discusses updates in the management of aortic stenosis, with a focus on use of TAVR.

Linda Gillam, MD, MPH, discusses the idea that the cardiology community may. be overtreating aortic stenosis.

A study of more than 130k with schizophrenia revealed significant variability in relapse and treatment failure rates across different antipsychotics.

New research reveals amyl nitrite (poppers) use is linked to dermatitis, with perianal and perioral regions most affected.

New research presented at CHEST 2024 highlights ensifentrine’s effectiveness in improving lung function, symptoms, and quality of life for COPD patients, regardless of disease severity.

The FDA's decision to issue a CRL was announced on October 08, 2024 and cites issues with the timing of the facility inspection.

Time-restricted eating, even without calorie restriction, improved glycemic control and cardiometabolic health in patients with metabolic syndrome.

Our September 2024 monthly recap in endocrinology spotlights regulatory updates, new guidelines, and the latest episodes of Diabetes Dialogue.

A review of 5 highly anticipated FDA decisions expected by year-end, including acoramidis for ATTR-CM, olezarsen for FCS, sotagliflozin for T1D and CKD, and more.

An EADV 2024 study suggests dupilumab use during pregnancy is generally safe and may lower risks of preterm labor, gestational hypertension, and diabetes.

Rahul Aggarwal, MD, discusses how the VICTORION-1 PREVENT trial eligibility criteria apply to the general US population.

The HCPLive Cardiology month in review for September 2024 spotlights ESC Congress 2024, Family Heart Global Summit, pipeline updates, and more!

Ruxolitinib cream offers an effective nonsteroidal treatment for mild to moderate atopic dermatitis, with proven efficacy and safety for sensitive skin areas.

Steve Nissen, MD, discusses how the cardiology community needs to learn from previous mistakes in uptake of LDL-C lowering therapies as it approaches an age of Lp(a)-lowering agents.

A comparison of the PALISADE and BALANCE trials, with commentary from a leading cardiologist, as the community nears a potential approval in FCS.

Christie Ballantyne, MD, discusses non-statin therapies, both approved and in development, for managing dyslipidemias from the floor of the 2024 Family Heart Global Summit.

A randomized trial suggests gefarnate significantly reduces triglycerides and LDL-C in older adults on statins with residual hypertriglyceridemia.

Temtokibart showed similar efficacy to dupilumab in treating moderate-to-severe atopic dermatitis, with faster skin hydration improvements in a phase 2a trial.

A Q&A with Nihar Desai, MD, on the PROMPT-Lipid trial and the potential of advancing technology for improving patient care in pragmatic ways.

Benjamin Scirica, MD, discusses the importance of team-based care and leveraging technology to optimize the management of cardiovascular risk factors.

Nihar Desai, MD, discusses the results of the PROMPT-Lipid trial while on-site at the 2024 Family Heart Global Summit.

Laurence Sperling, MD, discusses his presentation from the 2024 Family Heart Global Summit examining public health efforts for prevention of cardiovascular disease.

A handheld tool improved skin cancer detection in primary care, increasing diagnostic sensitivity to 96.3% compared to 83.9% without the device.

As advancements in valvular technology progress, Nguyen highlights the need for long-term data and multidisciplinary collaboration to improve patient outcomes.

The FDA has approved the Eversense 365, the world’s first 1-year continuous glucose monitor, with US availability expected in late 2024.

At Maui Derm NP+PA Fall 2024, bimekizumab data demonstrates a consistent safety profile in moderate to severe plaque psoriasis over 4 years, with decreasing event rates over time.

Leo Pharma announced the availability of a single-dose autoinjector of tralokinumab for moderate-to-severe atopic dermatitis, approved by the FDA in June 2024.